Cargando…

Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant

The 3C-like (3CL) protease of the severe acute respiratory syndrome (SARS) coronavirus is a key enzyme for the virus maturation. We found for the first time that the mature SARS 3CL protease is subject to degradation at 188Arg/189Gln. Replacing Arg with Ile at position 188 rendered the protease resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Akaji, Kenichi, Konno, Hiroyuki, Onozuka, Mari, Makino, Ayumi, Saito, Hiroyuki, Nosaka, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126698/
https://www.ncbi.nlm.nih.gov/pubmed/18845442
http://dx.doi.org/10.1016/j.bmc.2008.09.057
_version_ 1783516202625138688
author Akaji, Kenichi
Konno, Hiroyuki
Onozuka, Mari
Makino, Ayumi
Saito, Hiroyuki
Nosaka, Kazuto
author_facet Akaji, Kenichi
Konno, Hiroyuki
Onozuka, Mari
Makino, Ayumi
Saito, Hiroyuki
Nosaka, Kazuto
author_sort Akaji, Kenichi
collection PubMed
description The 3C-like (3CL) protease of the severe acute respiratory syndrome (SARS) coronavirus is a key enzyme for the virus maturation. We found for the first time that the mature SARS 3CL protease is subject to degradation at 188Arg/189Gln. Replacing Arg with Ile at position 188 rendered the protease resistant to proteolysis. The R188I mutant digested a conserved undecapeptide substrate with a K(m) of 33.8 μM and k(cat) of 4753 s(−1). Compared with the value reported for the mature protease containing a C-terminal His-tag, the relative activity of the mutant was nearly 10(6). Novel peptide-aldehyde derivatives containing a side-chain-protected C-terminal Gln efficiently inhibited the catalytic activity of the R188I mutant. The results indicated for the first time that the tetrapeptide sequence is enough for inhibitory activities of peptide-aldehyde derivatives.
format Online
Article
Text
id pubmed-7126698
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71266982020-04-08 Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant Akaji, Kenichi Konno, Hiroyuki Onozuka, Mari Makino, Ayumi Saito, Hiroyuki Nosaka, Kazuto Bioorg Med Chem Article The 3C-like (3CL) protease of the severe acute respiratory syndrome (SARS) coronavirus is a key enzyme for the virus maturation. We found for the first time that the mature SARS 3CL protease is subject to degradation at 188Arg/189Gln. Replacing Arg with Ile at position 188 rendered the protease resistant to proteolysis. The R188I mutant digested a conserved undecapeptide substrate with a K(m) of 33.8 μM and k(cat) of 4753 s(−1). Compared with the value reported for the mature protease containing a C-terminal His-tag, the relative activity of the mutant was nearly 10(6). Novel peptide-aldehyde derivatives containing a side-chain-protected C-terminal Gln efficiently inhibited the catalytic activity of the R188I mutant. The results indicated for the first time that the tetrapeptide sequence is enough for inhibitory activities of peptide-aldehyde derivatives. Elsevier Ltd. 2008-11-01 2008-09-26 /pmc/articles/PMC7126698/ /pubmed/18845442 http://dx.doi.org/10.1016/j.bmc.2008.09.057 Text en Copyright © 2008 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Akaji, Kenichi
Konno, Hiroyuki
Onozuka, Mari
Makino, Ayumi
Saito, Hiroyuki
Nosaka, Kazuto
Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
title Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
title_full Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
title_fullStr Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
title_full_unstemmed Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
title_short Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant
title_sort evaluation of peptide-aldehyde inhibitors using r188i mutant of sars 3cl protease as a proteolysis-resistant mutant
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126698/
https://www.ncbi.nlm.nih.gov/pubmed/18845442
http://dx.doi.org/10.1016/j.bmc.2008.09.057
work_keys_str_mv AT akajikenichi evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant
AT konnohiroyuki evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant
AT onozukamari evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant
AT makinoayumi evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant
AT saitohiroyuki evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant
AT nosakakazuto evaluationofpeptidealdehydeinhibitorsusingr188imutantofsars3clproteaseasaproteolysisresistantmutant